Which company’s drug information is Quizartinib?

Quizartinib (Quizartinib) is an innovative small molecule targeted drug developed and produced by the Japanese pharmaceutical company **Daiichi Sankyo, Inc.**. Daiichi Sankyo is a pharmaceutical company with global influence, and its R&D pipeline covers multiple fields such as oncology, cardiovascular diseases and central nervous system diseases. In the treatment field of acute myeloid leukemia (AML), Daiichi Sankyo is committed to developing targeted drugs targeting specific gene mutations to provide patients with personalized treatment options.

As an original drug, quizartinib has verified its efficacy and safety through rigorous clinical studies, and has especially shown significant anti-tumor effects in adult patients with newly diagnosed AML who are positive for FLT3-ITD. Daiichi Sankyo is responsible for the promotion, clinical research and drug production of Quizartinib globally, ensuring that drug quality complies with international Good Manufacturing Practices (GMP).

In addition,Daiichi Sankyo is also conducting multi-center clinical trials around the world to explore the application potential of quizartinib in different courses of treatment, combination chemotherapy regimens and maintenance therapy, promoting it to become an important part of the standard treatment plan for AML. Through cooperation with academic institutions and medical institutions around the world, Daiichi Sankyo continues to optimize the clinical use plan of quizartinib to further improve the treatment effect and reduce the risk of side effects.

To sum up, Quizartinib, as a FLT3-ITD targeted drug developed by Daiichi Sankyo, not only precisely targets leukemia cells in terms of mechanism, but also provides patients with reliable treatment options through high-quality production and global clinical verification. Its role in controlling disease progression, prolonging remission, and improving patient survival prognosis makes it one of the core targeted drugs for FLT3-ITD-positive AML, especially for those patients who are at risk of resistance to traditional chemotherapy.

References：https://www.vanflyta.com/en